Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study.

BACKGROUND Implantable sensors that monitor haemodynamics over time may be useful in patients with heart failure. This multicentre study assessed the feasibility of a system that has one sensor measuring absolute pressure and another measuring mixed venous oxygen saturation (SvO(2)). Both sensors were mounted on leads that were implanted in the right ventricle. METHODS Twenty-one patients with heart failure (NYHA II-III) were included. Comparisons were made to right heart catheterizations at implant and at 2, 6 and 12 months thereafter. Patients underwent several haemodynamic provocations during the catheterizations. RESULTS Overall, among functioning sensors, the IHM-1 values were highly correlated with reference values for all time points during all provocations, demonstrating high reproducibility and stability (r(2)=0.91, 0.79 and 0.78 for systolic, right ventricular diastolic and SvO(2), respectively). Although IHM-1 underestimated reference pressure values by 4.5 mmHg and SvO(2)by 1.6%, this difference was consistent across provocation and stable over 12 months of follow-up. Twelve of the 21 oxygen sensors failed to function and two pressure sensors had component failures. Preliminary analysis of long-term data revealed haemodynamic patterns that may be key indicators for therapeutic interventions. CONCLUSION This multicentre feasibility study demonstrated the accuracy and stability of sensors implanted in the right ventricle. The IHM-1, using right ventricular pressures and SvO(2), with improved performance, might be useful in the study of pathophysiological mechanisms and treatment interventions in heart failure.

[1]  R. Wilson,et al.  Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure. , 1996, Journal of cardiac failure.

[2]  D. Bresnahan,et al.  Initial experience with an implantable hemodynamic monitor. , 1996, Circulation.

[3]  D. Reynolds,et al.  Measurement of pulmonary artery diastolic pressure from the right ventricle. , 1995, Journal of the American College of Cardiology.

[4]  L. Rydén,et al.  Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. , 1995, Journal of cardiac failure.

[5]  Arjun D. Sharma,et al.  Development of a Rate Adaptive Pacemaker Based on the Maximum Rate‐of‐Rise of Right Ventricular Pressure (RV dP/dtmax) , 1992, Pacing and clinical electrophysiology : PACE.

[6]  C. Leddy,et al.  Hemodynamic effects of vasodilators and long-term response in heart failure. , 1984, Journal of the American College of Cardiology.

[7]  M. Packer Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. , 1988, Journal of the American College of Cardiology.

[8]  F. Ottenhoff,et al.  Long-term recording of cardiac output via an implantable haemodynamic monitoring device. , 1996, European heart journal.

[9]  L. Rydén,et al.  Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique. , 1998, European heart journal.

[10]  L Rydén,et al.  Monitoring of mixed venous oxygen saturation and pressure from biosensors in the right ventricle. A 24 hour study in patients with heart failure. , 1995, European heart journal.

[11]  L Stangeland,et al.  Long‐Term Clinical Performance of a Central Venous Oxygen Saturation Sensor for Rate Adaptive Cardiac Pacing , 1994, Pacing and clinical electrophysiology : PACE.

[12]  L. Stevenson,et al.  Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. , 1989, The American journal of cardiology.

[13]  M. Luu,et al.  Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. , 1992, Journal of the American College of Cardiology.